Fig. 6

Bortezomib inhibited glioma growth and sensitized glioma to TMZ in vivo. a Left part, representative images of subcutaneously xeno-transplanted glioma models in nude mice. About 1 week after subcutaneous injection of U87 cells, the mice were selected and randomized into four groups and were initiated treatment with bortezomib, TMZ, TMZ + bortezomib, or drug vehicle (DMSO). Right part, in vivo tumors volume was measured every 3 days with a vernier caliper, and same day collected data were compared among groups. ^ɑP < 0.01, ^βP < 0.05, compared with DMSO group; ^θP < 0.01, compared with bortezomib group; ^ϑP < 0.01, compared with TMZ group. b Left part, representative images of glioma lesions taken from the mice of each group. After treatment for 28 days, the nude mice were euthanized, and glioma lesions were taken off in intact. Right part, the weight of fresh glioma lesions. c Top part, representative images of IHC staining of FOXM1 and Survivin in glioma tissues from mice (scale bar, 100 μm). Bottom part, the IHC staining intensity of FOXM1 and Survivin were further quantified via Image-pro Plus 6.0. *P < 0.05; **P < 0.01. Bor bortezomib, TMZ temozolomide, DMSO dimethyl sulfoxide, IHC immunohistochemistry